论文部分内容阅读
将84例T2DM患者随机分为(各42例)应用BIAsp30和BHI30每日早晚餐前注射联合午餐后二甲双胍0.5g治疗12周,结果BIAsp30组早晚2hPG、HbA1c、改善β细胞功能、降低IR方面,优于BHI30组(P<0.05),且血糖达标所需时间短、低血糖率低(P<0.05);胰岛素用量、BMI、中h2PG下降值无明显差异(P>0.05)。结论对病程较短的T2DM患者,注射BIAsp30联合午餐后二甲双胍口服方案能更好地控制血糖、改善β细胞功能、降低IR。
Eighty-two patients with T2DM were randomly divided into two groups (n = 42 each). BIAsp30 and BHI30 were administered daily with or without pre-meal and post-lunch metformin 0.5g for 12 weeks. Results In the BIAsp30 group, 2hPG and HbA1c were improved sooner or later, (P <0.05), and the time required for achieving blood glucose compliance was short and the rate of hypoglycemia was low (P <0.05). There was no significant difference in the amount of insulin, BMI and h2PG (P> 0.05). Conclusion The oral administration of BIAsp30 combined with metformin after lunch can better control blood glucose, improve β-cell function and reduce IR in T2DM patients with shorter duration of disease.